Publicaties

Brunt TM, van Noorden M, Kamal RM, Dijkstra BAG, DeJong CA.  2016.  Epidemiology of Gamma-hydroxybutyrate (GHB) use and misuse and characteristics of GHB-dependent inpatients. The Neuropathology Of Drug Addictions And Substance Misuse.

Bruijnen CJWH, Kessels RP, Dijkstra BAG, Walvoort SJW, Wester AJ, DeJong CA.  2016.  Montreal Cognitive Assessment - Dutch (MoCA-D): een cognitieve screener in de Nederlandse reguliere verslavingszorg.

Bruijnen CJWH, Wester AJ, Markus W, DeJong CA, Kessels RP.  2013.  Screening of cognitive disorders in substance abuse patients using the Montreal Cognitive Assessment - Dutch Version (MoCA-D). Journal of the International Neuropsychological Society. 19(Suppl 2)

Bruijnen CJWH, Young SY, Marx M, Seedat S.  2019.  Social anxiety disorder and childhood trauma in the context of anxiety (behavioural inhibition), impulsivity (behavioural activation) and quality of life. South African Journal of Psychiatry. 25:1-7.

Bruijnen CJWH, Jansen M, Dijkstra BAG, Walvoort SJW, Lugtmeijer S, Markus W, de Jong CAJ, Kessels RPC.  2019.  The Montreal Cognitive Assessment (MoCA) as a cognitive screen in addiction health care: A validation study for clinical practice. Journal of Substance Use. 24(1)

Bruijnen CJWH, Dijkstra BAG, Walvoort SJW, Budy MJJ, Beurmanjer H, de Jong CAJ, Kessels RPC.  2020.  Psychometric properties of the Montreal Cognitive Assessment (MoCA) in healthy participants aged 18-70.. Int J Psychiatry Clin Pract. :1-8.

Bruijnen CJWH, Dijkstra BAG, Walvoort SJW, Markus W, VanDerNagel JEL, Kessels RPC, de Jong CAJ.  2019.  Prevalence of cognitive impairment in patients with substance use disorder. The Authors Drug and Alcohol Review .

Bruijnen CJWH, Dijkstra BAG, Walvoort SJW, Markus W, VanDerNagel JEL, Kessels RPC, DeJong CAJ.  2019.  Prevalence of cognitive impairment in patients with substance use disorder. Drug Alcohol Rev. 38(4):435-442.

Bruguera P, Ilzarbe D, Batalla A, Udina M, Roca JM, Pons A, Lomeña F, Martin-Santos R, Parellada E.  2014.  Clinical use of SPECT DaTSCAN in psychiatric population: one-year outcomes of a prospective case series. Psiquiatría Biológica. 21(1)

Blanco-Hinojo L, Pujol J, Harrison BJ, Macià D, Batalla A, Nogué S, Torrens M, Farré M, Deus J, Martin-Santos R.  2016.  Attenuated frontal and sensory inputs to the basal ganglia in cannabis users.. Addict Biol.

Blaauw E, Greeven PGJ, van Luijk B.  2012.  Diagnostiek en indicatiestelling. Handboek Forensische Verslavingszorg, In: E. Blaauw & H. Roozen (red.).. :77-104.

Binelli C, Muñiz A, Sanches S, Ortiz A, Navines R, Egmond E, Udina M, Batalla A, López-Sola C, Crippa JA et al..  2015.  New evidence of heterogeneity in social anxiety disorder: defining two qualitatively different personality profiles taking into account clinical, environmental and genetic factors. Eur Psychiatry. 30(1):160-5.

Binelli C, Subirà S, Batalla A, Muñiz A, Sugranyés G, Crippa JA, Farré M, Pérez-Jurado L, Martin-Santos R.  2014.  Common and distinct neural correlates of facial emotion processing in social anxiety disorder and Williams syndrome: A systematic review and voxel-based meta-analysis of functional resonance imaging studies.. Neuropsychologia. 64C:205-217.

Beurmanjer H, Kamal RM, de Jong CAJ, Dijkstra BAG, Schellekens AFA.  2018.  Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non-Randomized, Controlled Trial.. CNS Drugs. 32(5):437-442.

Beurmanjer H, Asperslag EM, Oliemeulen L, Goudriaan AE, De Jong CAJ, Schellekens AFA, Dijkstra BAG.  2019.  A Qualitative Approach in Understanding Illness Perception and Treatment Needs in Patients with Gamma Hydroxybutyrate Use Disorder.. Eur Addict Res. 25(5):248-255.

Beurmanjer H, Luykx JJ, De Wilde B, van Rompaey K, Buwalda VJA, de Jong CAJ, Dijkstra BAG, Schellekens AFA.  2020.  Tapering with Pharmaceutical GHB or Benzodiazepines for Detoxification in GHB-Dependent Patients: A Matched-Subject Observational Study of Treatment-as-Usual in Belgium and The Netherlands.. CNS Drugs. 34(6):651-659.

Bender S, Grohmann R, Engels RCME, Degner D, Dittmann-Balcar A, Rüther E.  2004.  Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics.. Pharmacopsychiatry. 37 Suppl 1:S46-53.

Bender S, Linka T, Wolstein J, Gehendges S, Paulus HJ, Schall U, Gastpar M.  2004.  Safety and efficacy of combined clozapine-lithium pharmacotherapy.. Int J Neuropsychopharmacol. 7(1):59-63.

Belgers M, Schellekens AFA.  2019.  Hoofdstuk 23 Somatische comorbiditeit bij verslaving. Handboek Verslaving.

Batalla A, Garcia-Rizo C, Castellví P, Fernandez-Egea E, Yücel M, Parellada E, Kirkpatrick B, Martin-Santos R, Bernardo M.  2013.  Screening for substance use disorders in first-episode psychosis: implications for readmission.. Schizophr Res. 146(1-3):125-31.

Batalla A, Bhattacharyya S, Yücel M, Fusar-Poli P, Crippa JA, Nogué S, Torrens M, Pujol J, Farré M, Martin-Santos R.  2013.  Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings.. PLoS One. 8(2):e55821.

Batalla A, Bargalló N, Gassó P, Molina O, Pareto D, Mas S, Roca JM, Bernardo M, Lafuente A, Parellada E.  2015.  Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls.. Transl Psychiatry. 5:e626.

Batalla A, Soriano-Mas C, López-Sola C, Torrens M, Crippa JA, Bhattacharyya S, Blanco-Hinojo L, Fagundo AB, Harrison BJ, Nogué S et al..  2014.  Modulation of brain structure by catechol-O-methyltransferase Val(158) Met polymorphism in chronic cannabis users.. Addict Biol. 19(4):722-32.

Batalla A, Homberg JR, Lipina TV, Sescousse G, Luijten M, Ivanova SA, Schellekens A, Loonen AJM.  2017.  The role of the habenula in the transition from reward to misery in substance use and mood disorders.. Neurosci Biobehav Rev.

Batalla A, Vera M, Torra M, Parellada E.  2010.  Antipsychotic treatment in a patient with schizophrenia undergoing hemodialysis.. J Clin Psychopharmacol. 30(1):92-4.